The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://antoncusy820698.wikiannouncing.com/7501118/retatrutide_vs_tirzepatide_a_comparative_analysis